BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19572791)

  • 1. Genous endothelial progenitor cell-capturing stent system: a novel stent technology.
    Klomp M; Beijk MA; de Winter RJ
    Expert Rev Med Devices; 2009 Jul; 6(4):365-75. PubMed ID: 19572791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.
    Aoki J; Serruys PW; van Beusekom H; Ong AT; McFadden EP; Sianos G; van der Giessen WJ; Regar E; de Feyter PJ; Davis HR; Rowland S; Kutryk MJ
    J Am Coll Cardiol; 2005 May; 45(10):1574-9. PubMed ID: 15893169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
    Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
    J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant intimal hyperplasia regression between 6 and 18 months following Genous™ endothelial progenitor cell capturing stent placement.
    Klomp M; Beijk MA; Tijssen JG; de Winter RJ
    Int J Cardiol; 2011 Mar; 147(2):289-91. PubMed ID: 21194767
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents.
    Cho HJ; Kim TY; Cho HJ; Park KW; Zhang SY; Kim JH; Kim SH; Hahn JY; Kang HJ; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Jul; 48(2):366-74. PubMed ID: 16843188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo and preclinical assessment of an endothelial progenitor cell capturing bioengineered stent.
    Yazdani SK; Kolodgie FD; Virmani R
    Minerva Cardioangiol; 2012 Feb; 60(1):11-21. PubMed ID: 22322570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin-collagen multilayer.
    Lin Q; Ding X; Qiu F; Song X; Fu G; Ji J
    Biomaterials; 2010 May; 31(14):4017-25. PubMed ID: 20149438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix.
    Woudstra P; de Winter RJ; Beijk MA
    Expert Rev Med Devices; 2014 Mar; 11(2):121-35. PubMed ID: 24484431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale of the TRI-stent adjudication study (TRIAS) program.
    Klomp M; Beijk MA; Verouden NJ; Tijssen JG; de Winter RJ;
    Am Heart J; 2009 Oct; 158(4):527-532.e1. PubMed ID: 19781410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
    Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
    Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stent coated with antibody against vascular endothelial-cadherin captures endothelial progenitor cells, accelerates re-endothelialization, and reduces neointimal formation.
    Lim WH; Seo WW; Choe W; Kang CK; Park J; Cho HJ; Kyeong S; Hur J; Yang HM; Cho HJ; Lee YS; Kim HS
    Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2798-805. PubMed ID: 22015656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to accelerate the endothelialization of stents.
    Ong AT; Aoki J; Kutryk MJ; Serruys PW
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):123-6. PubMed ID: 15787303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results after coronary stenting with the Genous™ Bio-engineered R stent™: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry.
    Silber S; Damman P; Klomp M; Beijk MA; Grisold M; Ribeiro EE; Suryapranata H; Wójcik J; Hian Sim K; Tijssen JG; de Winter RJ
    EuroIntervention; 2011 Feb; 6(7):819-25. PubMed ID: 21252015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design criteria for the ideal drug-eluting stent.
    Ako J; Bonneau HN; Honda Y; Fitzgerald PJ
    Am J Cardiol; 2007 Oct; 100(8B):3M-9M. PubMed ID: 17950830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects of drug-eluting stents in the coronary circulation.
    Steffel J; Tanner FC
    Herz; 2007 Jun; 32(4):268-73. PubMed ID: 17607532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the intimal response to a protein-modified stent in a tissue-engineered blood vessel mimic.
    Cardinal KO; Williams SK
    Tissue Eng Part A; 2009 Dec; 15(12):3869-76. PubMed ID: 19563259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.